Navigation Links
Melior Enters Research Collaboration with AstraZeneca
Date:8/19/2008

Melior Discovery, Inc. announced today that it has signed an agreement with AstraZeneca PLC under which Melior’s in-vivo theraTRACE indications discovery platform will be used to evaluate the therapeutic activity of selected AstraZeneca compounds.

EXTON, Pa. (Business Wire EON) August 19, 2008 -- "Our agreement represents a significant opportunity for Melior to deliver value to AstraZeneca through the application of our unique and innovative in vivo testing platform," said Andrew Reaume, PhD, President and CEO of Melior. "We look forward to a productive collaboration."

Melior Discovery Overview

Melior Discovery is leading the transformation of drug repositioning with its unique theraTRACE platform of multiplexed in vivo models. Melior is using theraTRACE to both build an internal pipeline of development candidates as well as sharing this capability with pharmaceutical and biotechnology company partners. In the former case, Melior identifies and develops "privileged" compounds that have been discontinued by other companies for lack of efficacy in their original indications. Melior is also able to identify appropriate compounds for repositioning by leveraging a close working relationship with the renowned medicinal chemist, Dr. Christopher Lipinski. In its partnered arrangements, Melior offers pharmaceutical partners an approach to expand their late-stage pipelines with safe, high-quality drug candidates

Melior Discovery is located in Exton, PA.

Read the full story at http://www.prweb.com/releases/melior/astrazeneca/prweb1226754.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1

Related biology technology :

1. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
2. American Laser Centers Opens Three Minneapolis-St. Paul Area Clinics
3. Chromos enters into an Arrangement Agreement
4. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
5. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
6. Albemarle Enters Ibuprofen Agreement with Dr. Reddys
7. WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing
8. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
9. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
10. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
11. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Melior Enters Research Collaboration with AstraZeneca 
(Date:11/30/2016)... , November 30, 2016 The global ... few players hold a dominant share in the overall ... Laboratories International, Inc., and Merck KGaA, held a lion,s ... Transparency Market Research observes that these companies are expected ... development products that are do not require rabbit pyrogen ...
(Date:11/30/2016)... VANCOUVER , Nov. 30, 2016 /PRNewswire/ -  Equicare ... coordination solutions, has been recognized as one of the ... 100, an annual international listing that distinguishes the top ... "We,ve pushed a great step forward this year continually ... growing our own customer base and team," says ...
(Date:11/30/2016)... -- Part of 5m$ Investment in Integrated Drug ... , ... today announced that it had successfully completed the expansion of ... increased the Screening Collection to over 400,000. The new compounds ... the company. This expansion, complemented by new robotics and compound ...
(Date:11/30/2016)... Triangle Park, NC (PRWEB) , ... November 30, ... ... development company engaged in the development of a new orally administered treatment for ... testing and neuroimaging results of a Phase 2a clinical trial of T3D-959 in ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):